BiotechTube

SUBLOCADE

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Use Disorder

Conditions

Opioid Use Disorder

Trial Timeline

Jan 1, 2021 → Dec 31, 2021

NCT ID
NCT04523792

About SUBLOCADE

SUBLOCADE is a phase 3 stage product being developed by Indivior PLC for Opioid Use Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04523792. Target conditions include Opioid Use Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04523792Phase 3Withdrawn
NCT03818399Phase 3Terminated

Competing Products

20 competing products in Opioid Use Disorder

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + NaloxegolAstraZenecaPhase 1
33
NKTR-118 + Usual careAstraZenecaPhase 3
77
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
85

Other Products from Indivior PLC

SUBLOCADEPhase 3
72